Spectral AI recognized in TIME's Top HealthTech Companies 2025 for innovative AI technology in wound care diagnostics.
Quiver AI Summary
Spectral AI, Inc., a Dallas-based company specializing in artificial intelligence for medical diagnostics, has been recognized in TIME's World’s Top HealthTech Companies 2025 list for its innovative contributions to wound care technology. This honor, which highlights the advancements of 400 leading HealthTech firms globally, is a testament to Spectral AI's success in developing its DeepView System, designed to provide clinicians with immediate assessments of burn wounds' healing potential. J. Michael DiMaio, the company's chairman, emphasized the significance of this accolade in marking the company's progress toward commercializing its AI-driven predictive technology. The DeepView System aims to enhance patient outcomes and lower healthcare costs by improving the accuracy and speed of treatment decisions.
Potential Positives
- Spectral AI was recognized by TIME as one of the World’s Top HealthTech Companies for 2025, highlighting the company’s innovative contributions to the healthcare technology sector.
- This recognition positions Spectral AI favorably within the industry, potentially enhancing its reputation and credibility among investors, partners, and customers.
- The inclusion in this prestigious list can lead to increased visibility and market interest, supporting future commercialization efforts for the DeepView technology.
- The acknowledgment reflects the progress and dedication of the team, which may boost employee morale and attract top talent to the company.
Potential Negatives
- While named to TIME’s World’s Top HealthTech Companies list, the announcement does not provide specific details about the company's recent financial performance or growth metrics, which may raise questions about overall stability and market position.
- The reliance on forward-looking statements without guarantees of performance may create uncertainty for investors, highlighting potential risks and challenges that could impact future results.
- The press release focuses heavily on recognition rather than concrete advancements or developments in the DeepView technology, which may lead to concerns about actual progress in commercialization efforts.
FAQ
What recognition did Spectral AI receive in 2025?
Spectral AI was named to TIME's World’s Top HealthTech Companies 2025 list for its innovative contributions in medical diagnostics.
What is the focus of Spectral AI's technology?
Spectral AI focuses on artificial intelligence for faster and more accurate treatment decisions in wound care, particularly for burn patients.
How does the DeepView System benefit clinicians?
The DeepView System provides objective assessments of burn wounds' healing potential, enabling better treatment decisions.
What criteria were used to evaluate the HealthTech companies?
Companies were evaluated based on financial performance, reputation analysis, and online engagement among thousands of HealthTech firms.
Where can I find more information about the DeepView System?
More information about the DeepView System is available at Spectral AI's official website, www.spectral-ai.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDAI Hedge Fund Activity
We have seen 13 institutional investors add shares of $MDAI stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AVANTAX PLANNING PARTNERS, INC. removed 231,336 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $573,713
- VANGUARD GROUP INC added 206,188 shares (+49.5%) to their portfolio in Q2 2025, for an estimated $511,346
- UBS GROUP AG added 99,580 shares (+135.3%) to their portfolio in Q2 2025, for an estimated $246,958
- RENAISSANCE TECHNOLOGIES LLC removed 96,025 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $110,428
- XTX TOPCO LTD added 49,640 shares (+inf%) to their portfolio in Q2 2025, for an estimated $123,107
- DNB ASSET MANAGEMENT AS added 43,024 shares (+inf%) to their portfolio in Q2 2025, for an estimated $106,699
- MARSHALL WACE, LLP added 42,041 shares (+inf%) to their portfolio in Q2 2025, for an estimated $104,261
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MDAI Analyst Ratings
Wall Street analysts have issued reports on $MDAI in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 04/02/2025
To track analyst ratings and price targets for $MDAI, check out Quiver Quantitative's $MDAI forecast page.
Full Release
DALLAS, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has been named to TIME’s World’s Top HealthTech Companies 2025 list. The ranking, released September 18, 2025, can be viewed on Time.com .
The list, compiled by TIME and Statista Inc., recognizes leading innovators advancing healthcare globally through technology. Companies were evaluated on financial performance, reputation analysis, and online engagement. Out of thousands of HealthTech companies reviewed, 400 were recognized for their outstanding performance across these categories.
J. Michael DiMaio, M.D., Chairman of Spectral AI, said, “Being named to TIME ’s World’s Top HealthTech Companies 2025 list alongside so many great companies is a huge milestone for Spectral AI and our DeepView technology. This recognition underscores the progress our team has made as we work toward global commercialization. Every team member continues to strive to deliver our innovative AI-based predictive wound care technology to the medical community.”
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown
®
” with its DeepView System. The DeepView System is being developed as a predictive device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView System, visit
www.spectral-ai.com
.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
For Media and Investor Relations, please contact :
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email:
[email protected]